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Abstract
Lysine acetylation is an important epigenetic mark regulating gene transcription and chro-
matin structure. Acetylated lysine residues are specifically recognized by bromodomains,
small protein interaction modules that read these modification in a sequence and acetyla-
tion dependent way regulating the recruitment of transcriptional regulators and chromatin
remodelling enzymes to acetylated sites in chromatin. Recent studies revealed that bromo-
domains are highly druggable protein interaction domains resulting in the development of a
large number of bromodomain inhibitors. BET bromodomain inhibitors received a lot of
attention in the oncology field resulting in the rapid translation of early BET bromodomain
inhibitors into clinical studies. Here we investigated the effects of mutations present as poly-
morphism or found in cancer on BET bromodomain function and stability and the influence
of these mutants on inhibitor binding. We found that most BET missense mutations localize
to peripheral residues in the two terminal helices. Crystal structures showed that the three
dimensional structure is not compromised by these mutations but mutations located in
close proximity to the acetyl-lysine binding site modulate acetyl-lysine and inhibitor binding.
Most mutations affect significantly protein stability and tertiary structure in solution, suggest-
ing new interactions and an alternative network of protein-protein interconnection as a con-
sequence of single amino acid substitution. To our knowledge this is the first report studying
the effect of mutations on bromodomain function and inhibitor binding.
Introduction
Epigenetics has been defined as heritable changes in phenotype that are the consequence of
changes in DNA sequence but are due to differences in the pattern of post-translational modifi-
cation present in histone, other nuclear proteins and in DNA [1]. Changes in post-translational
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modifications also called epigenetic marks is a principal mechanism regulating chromatin
structure and gene transcription and dysregulation of epigenetic marks has been linked to the
development of a large diversity of diseases. Acetylation of lysine residues (Kac) is one of the
most frequently occurring post-translational modifications which controls a vast array of
diverse cellular functions. Dysregulation of acetylation levels has been associated with the
development of many diseases in particular to cancer and enzymes regulating acetylation have
emerged as interesting targets for drug discovery [2–4]. Acetylation levels are reversibly main-
tained by a group of enzymes, the histone acetyl-transferases and histone deacetylases that
“write” and “erase” acetylation marks on histones [5]. Acetylation sites in proteins are specifi-
cally recognized by small helical interaction modules called Bromodomains (BRDs).
The relevant importance of BRDs in drug design is highlighted in recent studies that report
BRDs as a target site for the development of new cancer drugs [3, 6–9]. Inhibitors that specifi-
cally target the BET (Bromo and Extra Terminal) proteins selectively interfered with gene
expression that mediated cellular growth and evasion of apoptosis in cancer [10–12]. The stud-
ies of these inhibitors have suggested that inhibition of BRDs may have several potential clini-
cal applications [3, 13]. BET proteins (ubiquitously expressed BRD2, BRD3, BRD4 and testis-
specific BRDT) belong to the subfamily II of BRDs, sharing a common architecture comprising
two N-terminal BRDs, domain 1 and domain 2, that exhibit high level of sequence conserva-
tion as well as an extra terminal domain and a more divergent C-terminal recruitment domain.
Despite their low sequence identity, all BRDs share a conserved fold comprising a left-
handed bundle of four alpha helices, connected with a characteristic hydrophobic cleft between
two conserved loops [14]. This binding site specifically recognizes ε-aminoacetyl groups of
nucleosomal histone. The first bromodomains of BETs have a preference binding to di-acety-
lated Kac present in histone H4. The binding mode of the acetyl-lysine interaction is highly
conserved comprising an anchoring hydrogen bond to a conserved asparagine residue present
in most BRDs as well as a water mediated hydrogen bond to a conserved tyrosine residue [15].
BRD4 and BRD2 have crucial roles in cell cycle control [16, 17]. BRD2 and BRD4 remain
bound to mitotic chromatin [18]; this property has been suggested to be important for the
maintenance of epigenetic memory during cell division [19, 20]. Constitutive over-expression
of BRD2 in B-cells of transgenic mice results in the development of B-cell lymphoma and leu-
kaemia [21]. Gene rearrangements of BRD3 and BRD4 with a testis specific protein called
NUT (Nuclear protein in Testis) have been detected in aggressive carcinoma [22–24]. BRD3
expression is induced in activated lymphocytes and it is highly expressed in undifferentiated
embryonic stem cells, whereas expression levels are reduced upon endothelial differentiation
[25]. Down regulated expression or loss of BRD3 has been detected in biopsies of nasopharyn-
geal carcinomas [26] and altered expression levels have been found in bladder cancer [25].
Several mutations in BRDs have been identified in humans and they may play an important
role in several diseases but the functional consequences of the recorded mutations has not been
studied. These variants are nonsynonymous single nucleotide polymorphisms (nsSNPs), single
nucleotide variations occurring in the coding region and leading to a polypeptide sequence
with amino acid substitutions. A number of investigations have addressed the effect of nsSNPs
on protein stability, protein-protein interactions and protein functions for several other protein
families [27, 28]. Indeed, large-scale computational studies utilizing structural information
indicate that many nsSNPs may affect protein stability by either increasing or decreasing pro-
tein stability. However, only a detailed experimental analysis can unequivocally reveal the effect
of the missense mutation on protein function [29, 30].
Thus, a detailed characterization of BET bromodomain variants found in cancer will be
important to evaluate the role of these sequence alteration affecting bromodomain function
and potentially resistance to emerging treatment strategies. Indeed, recent reports already
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identified mechanisms by which cancer cells may evade treatment by BET bromodomain
inhibitors [31, 32]. We therefore report here the effect of BET bromodomain mutations found
in the cancer patients and annotated in the COSMIC database (http://cancer.sanger.ac.uk/
cosmic) [33] on bromodomain structure, the ability of BET bromodomains to bind acetylated
target sequences as well as inhibitors and the consequences of these mutations on the confor-
mational stability of the bromodomain fold.
Results
BET variants in cancer
Mutants that map to BET bromodomains were mined from the COSMIC database (http://
cancer.sanger.ac.uk/cosmic) [33] and were mainly identified BET variants, present in cancer of
the large intestine and lung or in hematopoietic malignancies. Most of the nsSNPS found in
the COSMIC database were present in BRD2. We identified seven mutants in BRD2 in the
sequence spanning both bromodomains (D160N, D160Y, Y153H, E140K, R100L, Q443H,
R419W), one in the second bromodomain of BRD3 (2) (H395R) and two mutations in the first
and second bromodomain of BRD4 (A89V, A420D) (Fig 1A). Most mutants were located on
the two terminal helices αB and αC, some of them in the proximity of the acetyl-lysine binding
site and in the loop regions (e.g. A89V in BRD4(1) and R100L in BRD2(1) are located in the
ZA loop) but no sequence variants were found in the highly sequence diverse αA helices. The
mutated residues present in the αB helix, namely E140K and Y153H in BRD2(1), R419W in
BRD2(2), A420D in BRD4(2), do not alter the conserved sequence motif ϕxxDϕxxϕϕxNϕxxY
(ϕ is a hydrophobic residue) that precedes the conserved arginine essential for Kac binding in
Fig 1. Alignment of BET bromodomain mutants. (A) Secondary structure elements are shown at the top of
the sequence alignment. Mutated residues are highlighted in red and studied mutations are listed. The
conserved asparagine (N391in BRD3(2) numbering) is highlighted in yellow. The green dots represent the
residues involved in binding with inhibitor JQ1 (PDB ID: 3ONI, 3S92, 3MXF). The residues underlined in blue
are involved in PFI-1binding (PDB ID: 4E96). (B) Location of the mutations. Shown are the first (left) and
second bromodomain of BRD2. The mutated residues are highlighted in ball and stick and the position of Cα
atoms are shown as a sphere. The main structural elements are labelled.
doi:10.1371/journal.pone.0159180.g001
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BET proteins [14] but the tyrosine residue Y153, mutated in BRD2(1), is highly conserved in
bromodomains suggesting a role in stabilizing the bromodomain fold. The residues D160 in
BRD2(1) and H395 in BRD3(2), mutated in D160N, D160Y and H395R, respectively are
located at the C-terminus of the BC loop, a region important for binding of Kac peptides and
inhibitors (Fig 1A). The residue D161, located in the Kac binding region, was also mutated into
D161N and D161Y to test the effect of this amino acid replacement in a region important for
acetylated peptides binding. The location of the identified mutants mapped onto the structures
of the first and second bromodomains is shown in Fig 1B [14]. All the mutations studied
involve surface exposed residues and do not affect conserved amino acids, with the exception
of Y153, a tyrosine residue present in all the sequence alignment in the family II BRDs (Fig 1).
Hence, the consequences of the mutations were not obvious and we generated recombinant
protein for each of the identified mutants using site directed mutagenesis and available bacte-
rial expression systems [14].
Effects of BET mutants on structure
In order to obtain insight on changes in three dimensional structure as well as local interaction
of the mutated sidechains we solved crystal structures of some of the generated mutants
(Fig 2). All structures (BRD2(1)R100L, BRD2(1)Y153H, BRD2(1)D161Y, BRD2(2)Q443H,
BRD3(2)H395R) were refined to high resolution maintaining favourable geometry (S1 Table).
The three dimension structure of the mutants was found to be highly conserved showing only
local structural alterations (Fig 2A). In the BRD2(1) mutant R100L the hydrogen bonds with
backbone residues in helix αA were lost but this did not result in significant structural changes
(Fig 2B). Mutations at BRD2(1) D161 as well as BRD2(2) Q443H (Fig 1) did also not result in
any significant structural rearrangements in the refined crystal structures (Fig 2C and 2D).
Effects of BET mutants on conformation in solution
The conformation in solution of all mutants was studied spectroscopically using CD and fluo-
rescence spectroscopy. The near-UV CD spectra of wild type bromodomains represent the
spectral contributions of all aromatic residues and was characterized by a strong negative peak
centred at around 280 nm and a positive one around 260 nm, accompanied, for BRD4(1) and
BRD2(2), by fine structure features in the region of 290 nm (Fig 2E–2I). Notably, the signifi-
cant differences observed in the near UV CD spectra of all the mutants indicated that their ter-
tiary structure arrangements are different from that of the corresponding wild type proteins, as
also suggested by differences observed in the intrinsic fluorescence spectra (S1 Fig). The intrin-
sic fluorescence spectra of most of the variants differed from the corresponding wild type pro-
teins mainly in intensity, which was either significantly decreased or enhanced. As expected,
based on differences in aromatic residue content, the maximal fluorescence emission wave-
length of BRD2(2) R419W was red shifted with respect to that of the wild type protein (S1C
Fig). These results pointed to local rearrangements of tertiary interactions for most of the
BRDs variants in solution.
The far-UV CD spectrum of all mutants indicated some differences in secondary structure
content probably due to differences in dynamic fluctuation in solution (Fig 3). The 222/208
ellipticity ratio, which is indicative of interhelical contacts present in helix bundle and coiled
coil structures as expected in the conserved bromodomain fold, differed in the various wild
type bromodomains and corresponded to 0.97, 0.98, 1.06, 1.16 and 2.15 in BRD2(1), BRD4(1),
BRD4(2), BRD2(2) and BRD3(2), respectively. The 222/208 ellipticity ratio is generally used to
distinguish between coiled coil helices ( 1.0) and non-interacting helices (0.8–0.9) [34, 35].
This ratio was unchanged for all the variants, except for the BRD2(1) mutants Y153H and
Consequences of Bromodomains Missense Mutations
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E140K that show a 222/208 ellipticity ratio below 1.0, corresponding to 0.86 and 0.91, respec-
tively (Fig 3A). The decrease in the 222/208 ellipticity ratio observed for these BRD2(1) vari-
ants suggested that a consequence of the amino acid substitutions was a perturbation of
interhelical contacts that resulted in structural differences in solution, despite the fact that
Y153 and E140 are not involved in any direct interactions with another helix and are solvent
exposed (Fig 1B).
All in all we conclude that despite the high structural conservation of mutants in crystal
structures the studied bromodomain mutants showed detectable changes of their spectroscopic
properties in solution suggesting differences in three dimension structures and the dynamic
properties of these mutants. Proteins are conformationally constrained in crystals and the
Fig 2. Structure of BETmutants and tertiary structure of mutants in solution. (A) Superimposition of wild
type BRD2(1) shown as a ribbon diagram with the mutants BRD2(1) R100L and D161Y shown as protein worm
in green and magenta, respectively. The mutated residues are shown in ball and stick representation and main
structural elements are labelled. (B) Details of interactions formed by R100 in the wild type compared to the
mutated residue. (C) Detailed view of BRD2(1) wild type and D161Y. (D) Superimposition of BRD2(2) shown as
a ribbon diagram and the mutant BRD2(2) Q443H shown as protein worm in blue. (E) Comparison of the near
UV CD spectra of wild type BRD2(1) and all generated mutants. (F) Comparison of the near UV CD spectra of
wild type BRD4(1) and the mutants BRD4(1) A89V. (G) Comparison of the near UV CD spectra of wild type
BRD2(2) and the mutants BRD2(2) R419W and Q443H. (H) Comparison of the near UV CD spectra of wild type
BRD3(2) and the mutants BRD3(2) H395R. (I) Comparison of the near UV CD spectra of wild type BRD4(2) and
the mutants BRD4(2) A420D. Near-UV CD spectra were recorded at 20°C in a 1.0-cm quartz cuvette in 20 mM
Tris/HCl, pH 7.5 containing 0.20 M NaCl and 2.00 mMDTT, as described in Materials and Methods.
doi:10.1371/journal.pone.0159180.g002
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studied bromodomain mutations may therefore alter domain plasticity and structural proper-
ties that are only apparent in solution.
Effects of BET mutants on acetyl-lysine peptide and inhibitor binding
Some of the BET mutants identified in cancer, are located in close proximity to the acetyl-
lysine binding site and we were therefore interested whether these mutants compromised the
ability of the bromodomain to bind acetylated histone peptides as well as BET inhibitors. To
address the first question we used biolayer interference (BLI), a technology that measures dif-
ferences in refractive index in a similar way as the widely used surface plasmon resonance tech-
nology, and a library of biotin labelled acetylated histone peptides. Using this peptide library
we measured the BLI response at 20 μM protein concentration on tips with immobilized acety-
lated and non-acetylated control peptides (Fig 4A). As expected, the first bromodomain of
BRD2(1) interacted strongly with polyacetylated peptides of histone H4 [14]. This interaction
was weakened by mutation in a region important for binding of Kac peptides (Fig 1A), such as
D161 (Fig 4A). Second bromodomains in BETs show much weaker interaction with histones
and other nuclear proteins that have been discussed as potential targets [36]. Indeed, we con-
firmed these reports and found only weak interaction with histones peptides that were present
in our peptide library for BRD3(2) (Fig 4A).
For studying the effects of the mutations on binding of BET inhibitors, we used two struc-
turally diverse panBET inhibitors: the thienodiazepine JQ1 [11] as well as the quinazolinone
PFI-1 [14, 37, 38]. Binding of JQ1 was only modestly affected by all mutations (S2 Table and
Fig 4D). Notably, the Kd for JQ1 was slightly increased for A420D, D161N and Y153H and
slightly decreased for all the other variants. A different trend is observed for PFI-1: in this case
Fig 3. Far-UV CD spectra of wild type bromodomains andmutants. Far-UV CD spectra were recorded at
20°C in a 0.1-cm quartz cuvette in 20 mM Tris/HCl, pH 7.5 containing 0.20 M NaCl and 0.40 mMDTT, as
described in Materials and Methods. Wild type spectra are shown as black solid lines and mutants are
coloured as indicated in the figure.
doi:10.1371/journal.pone.0159180.g003
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the Kd was slightly decreased for D161Y and A420D and was increased for all the other vari-
ants. The largest differences were observed for mutants of BRD3(2). H395R mutant and wild
type protein with both the inhibitors JQ1 and PFI-1; this variant showed a 3-fold lower Kd for
JQ1 and about 9-fold higher Kd for PFI-1(Fig 4E). Comparison with the crystal structure of
wild type BRD3(2) with JQ1 and the structure of BRD3(2) H395R suggested that the arginine
residue introduced by this mutant may form a more favourable hydrogen bond with the car-
bonyl oxygen of the ester link (Fig 4B and 4C). All titration experiments are compiled in S2
Table.
Fig 4. Binding of BET bromodomain mutants to acetylated histone peptides and inhibitors. (A) BLI
study showing the interaction of somemutants with acetylated histone peptides. Shown is the maximum
response at a protein concentration of 20 μM after subtraction of non-acetylated reference peptides using a
colour code as indicated in the figure capture. (B) Structure of BRD3(2) mutant H395R. The mutated residues
are highlighted. A nitrate molecule, present in the crystallization solution occupied the acetyl-lysine binding
site in BRD3(2) H395R. The conserved asparagine (N391) formed canonical hydrogen bonds with the
nitrated ion. (C) Superimposition of the wild type JQ1 complex with BRD3(2) H395R. (D) ITC experiments
measuring the interaction of the panBET inhibitor JQ1 with wild type BRD3(2) (black curve) and BRD3(2)
H395R (blue curve). Shown are raw titration heats (top panel) as well as normalized binding enthalpies as a
function of ligand/protein ratio (lower panel). The best fit to a single binding site model is shown as solid lines.
(E) ITC experiments showing the binding of the pan-BET inhibitor PFI-1 with BRD3(2) and the H395Rmutant.
A significant reduction in binding enthalpy and binding affinity is evident. Data on all ITC titrations are
summarized in S2 Table.
doi:10.1371/journal.pone.0159180.g004
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Effects of BET mutants on BRD stability
The thermal and thermodynamic stability of the wild type BRD2(1), BRD4(1) BRD2(2), BRD4
(2) and BRD3(2) were compared with the generated BET variants (Table 1).
It is noteworthy that all the natural variants studied, with the exception of BRD4(1) A89V,
showed a significant decrease in the melting temperature (Tm) ranging from 1.3°C for BRD2
(1) D161N to 10.0°C for BRD2(1) E140K, when compared to the wild type proteins. The ther-
mal stability of BRDs wild type and variants was investigated by continuously monitoring the
ellipticity changes at 222 nm between 20 and 80°C. The observed thermal unfolding occured in
an apparent two-state cooperative transition for all BRDs wild type and variants (S2 and S3
Figs). The midpoint of the unfolding, Tm, was calculated by plotting the first derivative of the
molar ellipticity at 222 nm, where the main amplitude was observed, as a function of tempera-
ture (S2A and S2B Fig, inset; S3A–S3C Fig, inset). It is noteworthy that for all the BRDs vari-
ants, with the exception of BRD2(2) variants, the amplitudes of the ellipticity changes at 222
nm, i.e. the difference between the ellipticity measured at the end (80°C) and that at the begin-
ning (20°C) of the thermal transition, were different from those measured for the wild type
(S2C, S2D and S3D–S3F Figs). In particular, the amplitude of the ellipticity changes at 222 nm
increased for all BRD2(1) variants, with the exception of D161N (S2C Fig), ranging from
Table 1. Melting temperatures and thermodynamic parameters for urea-induced unfolding equilibrium of BRDs wild type andmutants measured
by far-UV CD and fluorescence spectroscopy.
Tm (°C) ΔGH2O (kcal/mol) m (kcal/mol/M) [Urea]0.5 (M)
CD ([Θ]222) Fluorescence CD ([Θ]222) Fluorescence CD ([Θ]222) Fluorescence
BRD2(1)
Wild type 54.8 12.88 ± 0.93 12.91 ± 0.99 2.40 ± 0.17 2.23 ± 0.17 5.36 5.79
Y153H 47.8 6.39 ± 0.34 7.60 ± 0.61 1.49 ± 0.08 1.60 ± 0.13 4.30 4.75
E140K 44.0 9.40 ± 0.70 8.38 ± 0.63 2.16 ± 0.16 1.85 ± 0.14 4.35 4.54
R100L 49.0 7.66 ±0.87 ΔG1 = 8.20ΔG2 = 10.10 1.46 ± 0.16 m1 = 3.16 ± 0.66 m2 = 1.92 ± 0.14 5.42 2.47 ± 0.05 5.35 ± 0.02
D160N 49.0 8.78 ± 0.70 10.58 ± 0.82 2.03 ± 0.16 2.52 ± 0.19 4.32 4.20
D160Y 45.0 8.86 ± 0.59 8.71 ± 0.58 1.82 ± 0.12 1.80 ± 0.12 4.85 4.83
D161N 53.5 10.67 ± 0.91 9.89 ± 0.68 2.11 ± 0.33 2.09 ± 0.18 5.07 5.31
D161Y 50.0 9.50 ± 0.36 8.25 ± 0.47 1.71± 0.06 1.46 ± 0.08 5.55 5.63
BRD4(1)
Wild type 52.9 8.82 ± 0.49 11.39 ± 0.97 1.27 ± 0.07 1.56 ± 0.13 6.96 7.32
A89V 53.0 9.81 ± 0.49 10.60 ± 0.83 1.46 ± 0.07 1.56 ± 0.12 6.70 6.80
BRD2(2)
Wild type 53.0 7.97 ± 0.53 6.60 ± 0.39 1.50 ± 0.10 1.36 ± 0.08 5.29 4.86
Q443H 50.0 8.86 ±0.47 8.28 ± 0.40 1.77 ± 0.09 1.77 ± 0.09 5.01 4.68
R419W 45.0 7.95 ± 0.42 6.00 ± 0.36 1.72 ± 0.09 1.18 ± 0.07 4.63 5.10
BRD3(2)
Wild type 51.6 7.14 ± 0.63 6.68 ± 0.52 1.41 ± 0.12 1.51 ± 0.11 5.06 4.44
H395R 49.0 9.17 ± 0.63 7.80 ± 0.55 2.02 ± 0.14 1.90 ± 0.13 4.53 4.10
BRD4(2)
Wild type 54.0 8.66 ± 0.47 4.72 ± 0.23 1.59 ± 0.08 0.95 ± 0.05 5.43 4.95
A420D 51.0 9.10 ± 0.49 9.65 ± 0.53 1.75 ± 0.09 1.87 ± 0.10 5.20 5.15
The temperature-induced changes were followed by monitoring the ellipticity at 222 nm. The Tm values were calculated by taking the first derivative of the
ellipticity at 222 nm with respect to temperature. Urea-induced unfolding equilibrium data were measured at 10°C in 20 mM Tris/HCl, pH 7.5, containing 0.2
M NaCl and 200 μMDTT by monitoring ellipticity at 222 nm [Θ222] and intrinsic fluorescence emission. ΔG
H
2
O andm values were obtained from Eq 3;
[Urea]0.5 was calculated from Eq 2. Intrinsic fluorescence emission data of BRD2(1) R100L were fitted to Eq 5. Data are reported as the mean ± SE of the fit.
doi:10.1371/journal.pone.0159180.t001
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1.3-fold for E140K, R100L, and D161Y, to 1.4-fold for D160N and D160Y and to 1.5-fold for
Y153H. For the variants BRD3(2) H395R and BRD4(2) A420D a 1.6 and 1.2-fold increase of
thermal transition amplitude is observed. These results point to a larger extent of loss of sec-
ondary structure upon thermal unfolding when compared to the wild type protein.
The lower Tm values and the higher loss of secondary structure elements upon thermal
unfolding suggest that the point mutations induce a remarkable destabilization of the native
state of BRDs. The temperature-induced ellipticity changes for all BRDs wild type and mutants
were coincident with the heat-induced increase of the photomultiplier tube voltage (data not
shown) suggesting that the temperature-induced unfolding is accompanied by protein aggrega-
tion [39]. Aggregation occurred also when thermal scans were performed at a lower heating
rate with a low-temperature shifts of the apparent Tm; the differences between the apparent
Tm of wild type and variants were the same as those measured at higher heating rate (data not
shown). The observed transitions were irreversible as indicated by the spectra measured at the
end of the cooling phase that differ from those of the native proteins measured at the beginning
of the thermal transitions (data not shown).
The thermodynamic stability was studied by urea-induced equilibrium unfolding. BRD2(1),
BRD4(1) BRD2(2), BRD4(2) and BRD3(2) wild type and variants reversibly unfold in urea at
10°C. The effect of increasing urea concentrations (0–8 M) on the structure of BRDs variants
was analyzed by far-UV CD (S4A, S4B and S5A–S5C Figs) and fluorescence spectroscopy
(S4C, S4D and S5D–S5F Figs) and compared to the effect exerted on the corresponding wild
type. The same samples used to monitor the far-UV CD changes during the unfolding transi-
tion were used to monitor fluorescence emission changes, to allow a direct comparison of the
data. The urea-induced changes in 222 nm ellipticity of all the BRDs wild type and mutants
showed a sigmoidal dependence on denaturant concentration and follow an apparent two-
state transition without any detectable intermediate (S4A, S4B and S5A–S5C Figs). Incubation
of BRDs wild type and variants at increasing urea concentrations resulted in a progressive
change of the intrinsic fluorescence emission intensity and a red-shift of the maximal emission
wavelength from 345 nm, in the absence of denaturant, to about 366 nm, in 8 M urea (data not
shown). Determination of the red-shift of the intrinsic fluorescence emission was obtained by
calculating the intensity averaged emission wavelength, l, at increasing urea concentration
(S4C, S4D, S4A, S4B and S5D–S5F Figs). This parameter is an integral measurement, negligibly
influenced by the noise, and reflects changes in both the shape and the position of the emission
spectrum. The urea-induced changes in l of all the mutants are similar to that of the wild type
proteins, show a sigmoidal dependence on urea concentration and follow an apparent two-
state transition without any detectable intermediate, except for the variant of BRD2(1) R100L.
The thermodynamic parameters obtained from the analysis of the far-UV CD and fluores-
cence changes transitions are reported in Table 1. The difference between the free energy of
urea-induced unfolding, ΔGH2
O, of the variants and that of the wild type indicates a decrease in
thermodynamic stability of 2–6 kcal/mol for BRD2(1) variants and an increase of about 2 kcal/
mol for BRD3(2) mutant H395R. A minor increase in ΔGH2
O (about 1 kcal/mol) was observed
for all the other BRDs variants (Table 1). The decrease in ΔG values measured monitoring the
far-UV CD changes of the BRD2(1) variants Y153H, R100L, D160Y and D161Y may be mainly
referred to the lowerm values, with respect to the wild type proteins. An increase in both ΔG
andm values was observed only for the BRD3(2) mutant H395R. The changes inm values may
indicate differences in the solvent exposed surface area upon unfolding between the variants
and the wild type: decrease inm values is usually referred to a decrease in the solvent-exposed
surface area upon unfolding. This is frequently ascribed to an increase in the compactness of
the residual structure in the non-native state ensemble, rather than to an increase of the
Consequences of Bromodomains Missense Mutations
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accessible surface area of the native state [40–42]. A decrease inm value upon single mutation
has been also referred, in some cases, to the population of a third intermediate state during
chemical unfolding [43]; this is the case for R100L unfolding where an intermediate has been
detected by monitoring the fluorescence changes (S4C Fig, inset). In 8.0 M urea, the ellipticity
at 222 nm and the maximal fluorescence emission wavelength of the BRDs variants are compa-
rable to those of the corresponding wild type proteins (data not shown) and did not indicate
any increase in the structure of the non-native state to support the large decrease inm value
observed for the BRD2(1) variants Y153H, R100L, D160Y and D161Y. In native conditions,
the spectral properties of most of the variants point to tertiary structure arrangements different
from those of the wild type and, for BRD2(1) E140K and Y153H variants (Fig 2), the 222/208
nm ratio< 1.0 (Fig 3A) may suggest a less compact native state.
The values of the thermodynamic parameters obtained from far-UV CD were comparable
to those determined from fluorescence data for all the BRDs wild type, with the exception for
BRD4(1) and BRD4(2) (Table 1); a non-coincidence of the thermodynamic parameters
obtained by the two spectroscopic probes was also observed for the BRD2(2) variant R419W
(Table 1). The lack of coincidence of the thermodynamic parameters determined using differ-
ent spectral probes is generally considered as an indication that the unfolding does not follow a
simple two-state process and suggests the presence of an undetected intermediate in the
unfolding pathway. However, them values obtained from the analysis of the far-UV CD and
fluorescence unfolding transitions were within the range of those expected for a monomeric
protein of about 115 amino acid residues denatured in urea [44]. Indeed, the presence of a fold-
ing intermediate was evident for the BRD2(1) R100L whose reversible urea unfolding transi-
tion monitored by the changes in fluorescence intensity averaged emission wavelength l (S4C
Fig, inset) was fitted as a three-state unfolding process, according to Eq 5 (Table 1).
Discussion
Bromodomains (BRDs) dysfunction has been linked to the development of several diseases [4].
In these regards, BRDs have recently emerged as interesting targets for the development of spe-
cific protein interaction inhibitors [3]. The object of this study were three of the four BET pro-
teins BRD2, BRD3 and BRD4 and to our knowledge, this is the first spectroscopic
characterization in solution of human BRDs variants found in cancer. Wild type and variants
of BRD2(1), BRD4(1), BRD2(2), BRD3(2) and BRD4(2), were studied in order to investigate
the effect of amino acid substitutions on their structure in solution and on their thermal and
thermodynamic stability and interactions with peptides and inhibitors (Figs 1 and 2, S6 Fig).
The structures of some of the variants that showed the most significant changes in inhibitor
binding were determined by X-ray crystallography (Fig 2).
The single amino acid substitutions significantly affect the tertiary interactions of most of
the BRDs variants studied, as indicated by the differences in their near UV CD fine structure
and/or in the ellipticity amplitude, when compared to the corresponding wild type proteins.
Due to the usually surface exposed location of the mutated residues, the consequences of the
mutations were not obvious, however most of the amino acid substitutions in BRDs variants
involve changes in the charge of solvent exposed residues, that may alter protein stability.
Notably, the amino acid substitutions in most of the variants suggest an increase in side chain
flexibility for the mutated residue [45] that may be responsible for local changes in protein
dynamics. The changes in tertiary arrangements of most of the variants were also evident from
their intrinsic fluorescence spectra that showed differences in relative intensity and/or in the
maximum emission wavelength. Only the mutation of Ala89 to Val did not significantly affect
the tertiary contacts of BRD4(1), as judged by a comparison of its spectral properties and of its
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stability with those of the wild type. A loosening of the native tertiary structure was suggested
also by the changes in the far UV CD spectra of some BRDs variants, particularly those of
BRD2(1) Y153H and E140K for which the 222/208 ellipticity ratio below 1.0 points to a weak-
ening of the interhelical contacts [34, 35]. Consequently the thermal and thermodynamic sta-
bility of these two variants were significantly decreased, as expected from the role of the
conserved Y153 residue, located at the end of the αB helix, in stabilizing the bromodomain fold
[14]. On the other hand, the substitution of the negatively charged glutamate with a positively
charged lysine may induce local perturbations responsible for the observed destabilization,
despite the lack of interaction of the solvent exposed side chain of E140 in the crystal structure
of the wild type protein.
The thermal and thermodynamic stability of the BRD2(1) variants Y153H, E140K, R100L,
D160N, D160Y and D161Y were remarkably lower than the corresponding wild type: the Tm
values were at least 5 degrees below that of the wild type and the ΔG values are more than 3
kcal/mol lower than those of the wild type proteins (S3 Table). Amino acid substitutions in
BRD2(1) variants involved changes in the charge of solvent exposed residues which would be
expected to have a significant impact on protein stability. In general, the naturally occurring
point mutations in BRD2(1) variants induced a remarkable destabilization of the native state,
as suggested by the significant loss of secondary structure elements upon thermal unfolding
and by the decrease in Tm and/or in ΔG values, e.g. in the mutant of the conserved Y153. How-
ever, for the other BRDs variants, differently from what observed for those of BRD2(1), the per-
turbation of tertiary contacts were not always accompanied by changes in both thermal and
thermodynamic stability. The 8°C decrease in thermal stability of BRD2(2) R419W variant was
not paralleled by a drop of its thermodynamic stability measured by urea induced-unfolding.
Mutation of a charged arginine residue, solvent exposed, into an aromatic and more flexible
tryptophan [45] may induce tertiary changes and lead to a protein with different hydrophobic
interactions and, probably, more prone to thermal denaturation. On the other hand, for the
BRD3(2) variant H395R the Tm is 2.6°C lower than that of the wild type, whereas the unfold-
ing ΔG is even higher than that of the wild type, due to the higherm value of this variant
(Table 1). Interestingly, both the variants BRD2(2) R419W and BRD3(2) H395R displayed sig-
nificant differences in the overall far-UV CD ellipticity and in the tertiary arrangements, as
indicated by the difference of their intrinsic fluorescence emission and near UV CD spectra
with respect to the wild type, despite the fact that interhelical contacts in these variants were
unaffected by the mutation, as suggested by the 222/208 ellipticity ratio similar to that of the
wild type. In conclusion, the naturally occurring mutations in BRDs, caused by nsSNPs and
found in cancer result in proteins with significantly altered physico-chemical properties, such
as alteration of native tertiary contacts, loosening of the interhelical contacts or changes in
thermal and/or thermodynamic stability [46]. In conclusion, despite the high structural conser-
vation in crystal structures, the BRDs variants showed differences in spectral properties in solu-
tion that may suggest local structural changes and modifications of their dynamic properties.
The binding studies revealed that the BRD2(1) variants, namely Y153H, D161Y and D161N
and BRD3(2) H395R showed significant differences compared to the wild-type proteins. The
observed differences in inhibitor binding (S2 Table) may be referred to the fact that the
mutated residues are located in close proximity of the BC loop, a region important for binding
of Kac peptides and inhibitors (Fig 1A). Also the interactions with the acetylated histones pep-
tides of H2A, H2B, H3 and H4, although preserved, showed some differences indicating that
the mutations affect the binding interactions with the natural substrates. Interestingly, the
superimposition of the X-ray structures of some of the variants with those of the wild type,
revealed that the mutations did not cause overall misfolding of the structure (Figs 2 and 4).
Minor structural changes were observed in BRD3(2) H395R where the amino acid substitution
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resulted in a new hydrogen bond and affect interactions in the ligand binding site, as indicated
by the different inhibitor binding affinity. Notably the remarkable changes in the interactions
with histone recognition sequences and inhibitors, e.g. in the H395 mutant, were not accompa-
nied by significant changes in the thermal and or thermodynamic stability of this variant (Fig 4
and S3 Table). A close relationship between the stability and the inhibitor binding data can be
established only for Y153H which showed the largest differences in stability accompanied by a
significant decrease in binding affinity for JQ1 and PFI-1.
Taken altogether, our results indicate that the mutants of BRDs found in cancer tissues did
not alter significantly the overall folding. However, the significant alteration of the tertiary con-
tacts observed in solution and the notable decrease in protein stability suggested an increase in
conformational flexibility. All the mutated residues were solvent exposed, therefore they are
not supposed to alter the global folding; however, a mutation of a residue on the surface may
result in new and unknown interactions, thus the variants may acquire a new pattern of inter-
actions and establish a novel and alternative network of protein-protein interconnection [47,
48]. This may be particularly important in BRDs that are physiologically embedded in multi-
domain proteins and multi-subunit complexes.
Apart from PFI-1 binding to BRD3(2) H395R, the studied mutations are still inhibited by
two diverse BET inhibitors and it is therefore not expected that the studied mutants will lead to
drug resistance.
The results obtained from the study on BRDs nsSNPS may raise additional questions since
BRDs are involved in the activation of oncogenes expression and most of the variants are less
stable than the wild type, thus the variants might be expected to be less “deleterious”. Consider-
ing the pivotal role of BET proteins in the regulation of the transcription of growth-promoting
genes and cell cycle regulators, the phenotypic perturbations of BRDs variants may potentially
lead to oncogene activation thus significantly affect the tumour development [4].
Materials and Methods
Plasmids and site-directed mutagenesis
The plasmids harboring the BRDs wild type genes [14] were used to obtain mutant enzymes.
The wild type plasmids were subjected to site-directed mutagenesis using Quick Change Site-
directed Mutagenesis Kit (Stratagene), combined with specific sense and antisense mutagenic
oligonucleotides as shown in S4 Table. The presence of the desired mutations and the absence
of unwanted additional mutations were confirmed by inserts sequencing.
Protein expression and purification
Wild type and mutant proteins were expressed in E.coli. Rosetta cells transformed with the
selected plasmids were grown at 37°C in LB medium with Kan antibiotic to an OD595 = 0.6.
Upon reached desired OD temperature was lowered up to 18°C, cultures were grown overnight
after induction with 0.5 mM isopropyl-β-D-thiogalactopyranoside. Protein purification was
carried out at 4°C modifying the protocol indicated by Filippakopoulos et al. [11]. Cells from
one liter culture were collected by centrifugation, re-suspended in 50 ml of buffer A (50 mM
HEPES, pH 7.5, 0.5 M NaCl, 5% Glycerol and 0.5 mM tris(2-carboxyethyl)phosphine–HCl
(TCEP) containing a cocktail of EDTA-free protease inhibitors (Roche), sonicated in a Vibra-
cell 75115 sonicator with 5 s boosts and 9 s pause, on ice. The sonicated cells were centrifuged
and the supernatant, after an additional centrifugation at 15000 rpm, was applied to a 5 ml pre-
packed His Trap column (GE Healthcare) equilibrated in buffer A. The His- tagged fusion pro-
tein was eluted with 0.25 M imidazole in buffer A. The eluted protein was concentrated to a
final volume of 2.5 ml on an Amicon concentrator Ultra-15 (Millipore) and then applied to a
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PD-10 pre-packed column (GE Healthcare) to remove imidazole. The protein in buffer A was
cleaved by recombinant His-tagged tobacco etch virus (TEV) protease (kindly provided by
SK), overnight at 4°C. The digested mixture containing TEV protease, the His-tag and the
cleaved protein was applied to a 5 ml pre-packed His Trap column (GE Healthcare) previously
equilibrated in buffer A. The flow through containing the protein without His-tag was col-
lected, and checked for purity and size by SDS–PAGE on a pre-casted NuPage 4–12% bis-Tris
polyacrylamide gel (Invitrogen) (S7 and S8 Figs). Gels were stained with Coomassie blue R-
250. The protein without His-tag was used for all structural and stability experiments. The
mutant and wild type enzymes obtained were approximately 70 mg from one liter culture. Pro-
tein quantification was determined according to OD280 measurement using respective molar
extinction coefficients ε of each protein, calculated according to Gill and Hippel [49].
Spectroscopic measurements
For intrinsic fluorescence emission measurements, the absorbance of the protein solutions at
280 nm was 0.10 AU, corresponding to a protein concentration ranging over 50.0–100 μg/mL.
Intrinsic fluorescence emission measurements were carried out at 10°C with a LS50B spectro-
fluorimeter (Perkin-Elmer) using a 1.0 cm path length quartz cuvette. Fluorescence emission
spectra were recorded from 300 to 450 nm (1 nm sampling interval), with the excitation wave-
length set at 295 nm. For far-UV (190–250 nm) CD spectra, the absorbance of the protein solu-
tions at 280 nm was 0.18 AU, corresponding to a protein concentration ranging over 100–
190 μg/ml (0.4 mM DTT, 0.1 cm path length quartz cuvette) or 0.10 AU, corresponding to a
protein concentration ranging over 50.0–100 μg/ml. (0.2 mMDTT, 0.2 cm path length quartz
cuvette). For near-UV (250–320 nm) CD spectra, the absorbance of the protein solutions at
280 nm was 2.2 AU, corresponding to a protein concentration ranging over 1.25–2.28 mg/mL
(2.0 mM DTT, 1.0 cm path length quartz cuvette). The results obtained from CD measure-
ments were expressed as the mean residue ellipticity ([Θ]), assuming a mean residue molecular
mass of 110 per amino acid residue. All spectroscopic measurements were carried out at 10°C
in 20 mM Tris-HCl pH 7.5 containing 0.20 M NaCl.
Urea-induced equilibrium unfolding
For equilibrium transition studies, BRDs wild type and variants (final concentration ranging
over 50.0–100 μg/ml) were incubated at 10°C at increasing concentrations of urea (0−8 M) in
20 mM Tris/HCl, pH 7.5, in the presence of 0.2 M NaCl and 200 μMDTT. After 10 min, equi-
librium was reached and intrinsic fluorescence emission and far-UV CD spectra (0.2-cm
cuvette) were recorded in parallel at 10°C. To test the reversibility of the unfolding, BRDs wild
type and variants were unfolded at 10°C in 7.5 M urea at protein concentration ranging over
0.5–1.0 mg/ml in 20 mM Tris/HCl, pH 7.5, in the presence of 2 mMDTT and 0.2 M NaCl.
After 10 min, refolding was started by 10-fold dilution of the unfolding mixture at 10°C into
solutions of the same buffer used for unfolding containing decreasing urea concentrations. The
final protein concentration ranged over 50.0–100 μg/mL. After 24 h, intrinsic fluorescence
emission and far-UV CD spectra were recorded at 10°C. All denaturation experiments were
performed in triplicate.
Thermal denaturation experiments
BRDs variants and wild type (protein concentration ranging over 0.10–0.20 mg/ml) were
heated from 20°C to 80°C in a 0.1 cm quartz cuvette with a heating rate of 1 degree x min-1
controlled by a Jasco programmable Peltier element. The dichroic activity at 222 nm and the
PMTV were continuously monitored in parallel every 0.5°C [39]. All the thermal scans were
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corrected for the solvent contribution at the different temperatures. Melting temperature (Tm)
values were calculated by taking the first derivative of the ellipticity at 222 nm with respect to
temperature. All denaturation experiments were performed in triplicate.
Bio-layer Interferometry
In Bio-layer Interferometry (BLI) experiment the affinity between histones acetylated peptides
and the proteins was measured. The proteins (20 μM) were dialyzed against the assay buffer
(25 mMHepes pH 7.5, 100 mMNaCl and 0.01% TWEEN). The biotinylated acetylated pep-
tides of the H2A, H2B, H3 and H4 histones were immobilized onto strepdavidin biosensor
(FòrteBio). All binding experiments were conducted at 25°C using an OctetRed 384 instrument
(FòrteBio). Common cycles steps for analysis included 120 s of biosensor baseline equilibration
step, associations in wells containing the free label protein for 240 s, and dissociations in buffer
wells for 240 s. Reference subtraction was performed with the FòrteBio data analysis software
to subtract the effect of baseline drift and the effect of nonspecific binding to biosensor tips
without immobilized peptides.
Data analysis
Far-UV CD spectra recorded as a function of urea concentration were analyzed by a singular
value decomposition algorithm (SVD) using the software MATLAB (Math-Works, South
Natick, MA) to remove the high frequency noise and the low frequency random errors and
determine the number of independent components in any given set of spectra. CD spectra in
the 213–250 nm region were placed in a rectangular matrix A of n columns, one column for
each spectrum collected at each time. The Amatrix is decomposed by SVD into the product of
three matrices: A = USVT, where U and V are orthogonal matrices and S is a diagonal matrix.
The Umatrix columns contain the basis spectra and the Vmatrix columns contain the urea
dependence of each basis spectrum. Both U and V columns are arranged in terms of decreasing
order of the relative weight of information, as indicated by the magnitude of the singular values
in S. The diagonal Smatrix contains the singular values that quantify the relative importance of
each vector in U and V. The signal-to-noise ratio is very high in the earliest columns of U and
V while the random noise is mainly accumulated in the latest U and V columns. The wave-
length averaged spectral changes induced by increasing denaturant concentrations are repre-
sented by the columns of matrix V; hence, the plot of the columns of V versus the denaturant
concentrations provides information about the observed transition.
The changes in intrinsic fluorescence emission spectra at increasing urea concentrations
were quantified as the intensity-averaged emission wavelength, l, [50] calculated according to
l ¼
X
ðIiliÞ=
X
ðIiÞ ð1Þ
where λi and Ii are the emission wavelength and its corresponding fluorescence intensity at that
wavelength, respectively. This quantity is an integral measurement, negligibly influenced by
the noise, which reflects changes in the shape and position of the emission spectrum.
Urea-induced equilibrium unfolding transitions monitored by far-UV CD ellipticity and
intrinsic fluorescence emission changes were analysed by fitting baseline and transition region
data to a two-state linear extrapolation model [51] according to
DGunfolding ¼ DGH2O þm½Urea ¼  RTlnKunfolding ð2Þ
where ΔGunfolding is the free energy change for unfolding for a given denaturant concentration,
ΔGH2
O the free energy change for unfolding in the absence of denaturant andm a slope term
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which quantifies the change in ΔGunfolding per unit concentration of denaturant, R the gas con-
stant, T the temperature and Kunfolding the equilibrium constant for unfolding. The model
expresses the signal as a function of denaturant concentration:
yi ¼
yN þ sN½Xi þ ðyU þ sU½XiÞ  exp½ðDGH2O m½XiÞ=RT
1þ exp ðDGH2Om½XiÞ
RT
h i ð3Þ
where yi is the observed signal, yU and yN are the baseline intercepts for unfolded and native
protein, sU and sN are the baseline slopes for the unfolded and native protein, [X]i the denatur-
ant concentration after the ith addition, ΔGH2
O the extrapolated free energy of unfolding in the
absence of denaturant,m the slope of a ΔGunfolding versus [X] plot. The denaturant concentra-
tion at the midpoint of the transition, [Urea]0.5, according to Eq 2, is calculated as:
½Urea0:5 ¼ DGH2O=m ð4Þ
The denaturation curve obtained by plotting the fluorescence changes of the BRD2(1) vari-
ant R100L induced by increasing urea concentrations was fitted to the following equation
assuming a three-state model:
F ¼ FN þ exp mIN
½ureaD50IN
RT
   FI þ FUexp mUI ½ureaD50UIRT
  
1þ exp mIN ½ureaD50INRT
   1þ exp mUI ½ureaD50UIRT
   ð5Þ
where F is l, calculated according to Eq 1,m is a constant that is proportional to the increase in
solvent-accessible surface area between the two states involved in the transition, D50I-N and
mI-N are the midpoint andm value for the transition between N and I, respectively, and D50U-I
andmU-I are the midpoint andm value for the transition between I and U, respectively [52].
The l of the intermediate state (I), FI, is constant whereas that of the folded state (N) and of
the unfolded state (U), FN and FU, respectively, has a linear dependence on denaturant concen-
tration
FN ¼ aN þ bN½urea ð6Þ
FU ¼ aU þ bU½urea ð7Þ
where aN and aU are the baseline intercepts for N and U, bN and bU are the baseline slopes for
N and U, respectively. All unfolding transition data were fitted by using Graphpad Prism 5.04.
Isothermal Titration Calorimetry
Isothermal titration calorimetry (ITC) experiments were performed at 20°C using a MicroCal
VP-ITC calorimeter. BRDs proteins were extensively dialyzed with an Amicon Ultrafiltration
device against the assay buffer (50 mMHepes, pH 7.5, 100 mMNaCl, 0.5 mM TCEP). The
assay buffer was also used to dilute the inhibitors 50 mMDMSO stock solutions to the experi-
ment final concentration (15 μM). In all the experiments the inhibitors JQ1 or PFI-1 were
placed in the sample cell under continuous stirring while the protein solution (ranging concen-
tration between 200 and 250 μM) was loaded into the syringe injector. The titrations curves
implied 30 injections of 6 μL at 180 s intervals. The thermodynamic data were processed with
Origin 7.0 software provided by MicroCal.
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Protein crystallization and structure determination
Aliquots of the purified proteins were set up for crystallization using a mosquito1 crystallization
robot (TTP Labtech). Coarse screens were typically setup onto Greiner 3-well plates using three
different drop ratios of precipitant to protein per condition (100+50 nL, 75+75 nL and 50+100
nL). All crystallizations were carried out using the sitting drop vapour diffusion method at 4°C
and were crystallized as described [14]. Crystals were cryo-protected using the well solution sup-
plemented with additional ethylene glycol and were flash frozen in liquid nitrogen. Data were
collected at diamond beamline I04 at a wavelength of 1.0121 Å. Indexing and integration was
carried out using MOSFLM [53] and scaling was performed with SCALA [54]. Initial phases
were calculated by molecular replacement with PHASER [55] using available structures of wild
type proteins [14]. Initial models were built by ARP/wARP [56] and building was completed
manually with COOT [57]. Refinement was carried out in REFMAC5 [58]. Thermal motions
were analyzed using TLSMD [59] and hydrogen atoms were included in late refinement cycles.
Supporting Information
S1 Fig. Intrinsic fluorescence emission spectra of wild type bromodomains and mutants.
Intrinsic fluorescence emission spectra were recorded at 20°C in 20 mMTris/HCl, pH 7.5 contain-
ing 0.20 MNaCl and 200 μMDTT (295 nm excitation excitation wavelength) as described in
Materials andMethods. The absorbance at 280 nm was 0.10 AU for all the protein solutions. Wild
type spectra are shown as black solid lines and mutants are coloured as indicated in the figure.
(TIF)
S2 Fig. Thermal unfolding transition of BRD2(1) and BRD4(1) wild type and variants
studied by CD spectroscopy.Wild type and variants were heated from 20°C to 80°C in a
0.1-cm quartz cuvette at 0.2 mg/ml in 20 mM Tris/HCl, pH 7.5 containing 0.20 M NaCl and
0.40 mM DTT and the molar ellipticity at 222 nm ([Θ222]) was monitored continuously every
0.5°C. Normalized [Θ222] of BRD2(1) (A), BRD4 (1) (B); the insets show the first derivative of
the same data as in (A) and in (B). (C) and (D) [Θ222] before normalization.
(TIF)
S3 Fig. Thermal unfolding transition of BRD2(2), BRD3(2) and BRD4(2) wild type and vari-
ants studied by CD spectroscopy.Wild type and variants were heated from 20°C to 80°C in a
0.1-cm quartz cuvette at 0.2 mg/ml in 20 mM Tris/HCl, pH 7.5 containing 0.20 MNaCl and 0.40
mMDTT and the molar ellipticity at 222 nm ([Θ222]) was monitored continuously every 0.5°C.
Normalized [Θ222] of BRD2(2) (A), BRD3 (2) (B), BRD4(2) (C); the insets show the first deriva-
tive of the same data as in (A), (B) and in (C). (D), (E) and (F) [Θ222] before normalization.
(TIF)
S4 Fig. Urea-induced equilibrium unfolding of BRD2(1) and BRD4(1) wild type and vari-
ants. (A) and (B) Normalized molar ellipticity at 222 nm ([Θ]222) reported after removal of the
high-frequency noise and the low-frequency random error by SVD; (C) and (D) Normalized
intensity-averaged emission wavelength (l). The continuous lines represent the nonlinear fitting
of the normalized molar ellipticities at 222 nm and of the normalized intensity-averaged emis-
sion wavelength data to Eq 3, at increasing denaturant concentrations, calculated as described in
Materials and Methods. The inset in (C) shows the three-state unfolding of BRD2(1) R100L var-
iant fitted according to Eq 5. The reversibility points (empty circles) are shown, for clarity, only
for the wild type and for R100L and were not included in the nonlinear regression analysis. All
the spectra were recorded at 10°C as described in Materials and Methods.
(TIF)
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S5 Fig. Urea-induced equilibrium unfolding of BRD2(2), BRD3(2) and BRD4(2) wild type
and variants. (A), (B) and (C) Normalized molar ellipticity at 222 nm ([Θ]222) reported after
removal of the high-frequency noise and the low-frequency random error by SVD; (D), (E)
and (F) normalized intensity-averaged emission wavelength (l). The continuous lines repre-
sent the nonlinear fitting of the normalized molar ellipticities at 222 nm and of the normalized
intensity-averaged emission wavelength data to Eq 3, at increasing denaturant concentrations,
calculated as described in Materials and Methods. The reversibility points (empty circles) are
shown, for clarity, only for the wild type and were not included in the nonlinear regression
analysis. All the spectra were recorded at 10°C as described in Materials and Methods.
(TIF)
S6 Fig. Details of the environment of residues variants in BRD2. Shown is a structural over-
view (top left) and details of interactions with neighbouring residues within a radius of 6 Å.
The mutated residues are shown in ball and stick representation and main structural elements
are labeled.
(PDF)
S7 Fig. SDS-PAGE analysis of BRD2(1) and BRD4(1) wild type and variants. Lane 1, protein
molecular mass markers; lane 2, wild type protein with His-tag; lane 3, wild type protein after
overnight treatment with TEV protease; lane 4, purified wild type protein without His-tag. (A)
BRD2(1) lane 5–11, purified variants without His-tag (15 kDa); (B) BRD4(1) lane 5, purified vari-
ant without His-tag (15 kDa). All the proteins were cleaved by TEV protease overnight at 4°C
and purified on a His Trap column. The flow through containing the purified proteins without
His-tag was collected and analyzed by SDS–PAGE. Gels were stained with Coomassie blue R-250.
(PDF)
S8 Fig. SDS-PAGE analysis of BRD2(2), BRD3(2) and BRD4(2) wild type and variants. Lane
1, protein molecular mass markers; lane 2, wild type protein with His-tag; lane 3, wild type pro-
tein after overnight treatment with TEV protease; lane 4, purified wild type protein without His-
tag. (A) BRD2(2) lane 5 and 6, purified variants without His-tag (13 kDa); (B) BRD3(2) lane 5,
purified variant without His-tag (13 kDa); (C) BRD4(2) lane 5, purified variant without His-tag
(15 kDa). All the proteins were cleaved by TEV protease overnight at 4°C and purified on a His
Trap column. The flow through containing the purified proteins without His-tag was collected
and analyzed by SDS–PAGE. Gels were stained with Coomassie blue R-250.
(PDF)
S1 Table. Data collection and refinement statistics.
(PDF)
S2 Table. Dissociation constants and thermodynamic parameters from isothermal titration
calorimetry assays. In all cases proteins were titrated into the ligand solution (reverse titra-
tion).
(PDF)
S3 Table. Structural location and difference in melting temperature and in free energy of
urea-induced unfolding of BRDs wild type and mutants.
(PDF)
S4 Table. List of oligonucleotides used for site-directed mutagenesis.
(PDF)
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